Womens Health: Worldwide Prescription Drug Markets
The past 25 years have seen unprecedented advancements in the area of women’s health. A number of events have helped to bring the concerns of women’s health to the forefront of medicine but the most significant was the women’s health movement, which increased attention to women’s health issues and the shortcomings of traditional medical practice and research. The National Institutes of Health, the American Medical Association, and the Office of Research on Women’s Health were all instrumental in affecting changes. Large studies are now conducted to gather data on the prevention and treatment of the major causes of death in middle-aged and older women, including cancer and osteoporosis. A number of societies have been established to bring attention to serious shortcomings and unmet needs in women’s health research worldwide with the focus on the study of diseases that affect only women and the secondary influence of reproduction on other physiological systems. Thanks to insistent congresswomen, women’s health activists, pressure from advocacy groups like the National Women’s Health Network and the Public Citizen’s Health Research Group, women’s health issues have risen to the public awareness.
The market for prescription drugs to treat the constellation of conditions that make up the discipline of women’s health has follow right along with the consciousness raising efforts. Since Kalorama’s last edition of this study, not only have revenues grown almost across all sectors, but the R&D pipeline has virtually exploded, setting up both great potential for the years ahead and some difficult competitive challenges.
This report provides market size, growth, and share for the following product categories:
- Autoimmune diseases
- Cancer
- Gynecological and Sexually Transmitted Diseases
- Hormones
- Osteoporosis
- Urinary Disorders
Revenues from these segments are not reported in total, as certain segments affect both men and women. The analysis and market data in this report estimate revenues associated with therapeutics for women only. Segmentation within each category is by major drug type and by geographic region (U.S., Europe, Japan, ROW). All market data pertain to the U.S. market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2005. Historical data are provided for each of the years 2000 through 2005, and forecast data are provided for each of the years 2006 through 2010. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2005 base year.
In addition to market data, the report contains extensive product pipeline information, competitor profiles, and discussions of the major industry issues and trends shaping the market.
The information and analysis presented in this report are based on an extensive survey of senior management in the prescription women’s health drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 36 industry executives and product managers to validate and obtain expert opinion on current and future trends in the women’s health industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.
Table of Contents
Chapter One: Executive Summary
- Scope and Methodology
- Size and Growth of the Market
- Trends Affecting the Market
- Market Outlook
Chapter Two: Introduction and Overview
- History of Women’s Health
- Female Reproductive System
- Hormone Regulation
- Demographics
- Epidemiology
- Autoimmune Disease
- Cancer
- Gynecological Infection and Sexually Transmitted Disease
- Hormone-Related Indications
- Osteoporosis
- Urinary Bladder Disorders
- Lifestyle Patterns
Chapter Three: Autoimmune Diseases
- Overview
- Chronic Fatigue Syndrome
- Treatment
- Fibromyalgia
- Treatment
- Rheumatoid Arthritis
- Treatment
- Scleroderma
- Treatment
- Sjogren’s Syndrome
- Treatment
- Systemic Lupus Erythematosus
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- 406381
- Anergix RA
- Ampligen
- Actemra
- Apilmod
- Arcoxia
- CDP 870
- CTLA 41G
- Denosumab
- Interleukin (IL-1)
- LymphoStat-B
- MabThera
- Milnacipran
- Prestara
- Prexige
- Prograf
- Org 39141
- Riquent
- Veldona
- Competitive Market
Chapter Four: Cancer
- Overview
- Breast Cancer
- Overview
- Treatment
- Cervical Cancer
- Overview
- Treatment
- Endometrial Cancer
- Overview
- Treatment
- Ovarian Cancer
- Overview
- Treatment
- Vaginal Cancer
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Advexin
- Arzoxifene
- Atamestane
- Avastin
- BrevaRex
- Cervarix
- Combidex
- Edotecarin
- Evista
- Herceptin
- Ixabepilone
- Lapatinib
- Lasofoxifene
- MDX-010
- Myocet
- OvaRex
- Pemtumomab
- Tavocept
- Taxoprexin
- Telcyta
- Temsirolimus
- Tykerb
- Vinorelbine IV
- Xinlay
- XRP 98
- Xytotax
- Yondelis
- Competitive Market
Chapter Five: Gynecological Infections and Sexually Transmitted Diseases
- Overview
- AIDS
- Overview
- Treatment
- Agenerase
- Aptivus
- Combivir
- Crixivan
- Entriva
- Fortovase
- Fuzeon
- Hivid
- Invirase
- Kaletra
- Kivexa
- Lexiva
- Prezista
- Rescriptor
- Reyataz
- Sustiva
- Trizivir
- Truvada
- Viracept
- Viramune
- Bacterial Vaginosis
- Overview
- Treatment
- Cervical Dysplasia
- Overview
- Treatment
- Chlamydia
- Overview
- Treatment
- Condyloma Acuminata
- Overview
- Treatment
- Aldara
- Alferon N Injection
- Condylox
- Gardasil
- Genital Herpes
- Overview
- Treatment
- Zovirax
- Gonorrhea
- Overview
- Treatment
- Hepatitis
- Overview
- Treatment
- Baraclude
- Pelvic Inflammatory Disease
- Overview
- Treatment
- Syphilis
- Overview
- Treatment
- Toxic Shock Syndrome
- Overview
- Treatment
- Yeast Infections
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Ampligen
- Aplaviroc
- BufferGel
- Carraguard
- Clevudine
- HepeX-B
- Hyphanox
- IFN-alpha Lozenge
- Interferon Alfacon/Ribaviron Combination
- Maraviroc
- Multiferon
- PRO 2000
- Proleukin
- Resiquimod
- SAVVY
- Simplirix
- SPO1A
- Telbivudine
- Ushercell
- Zadaxin
- Competitive Market
Chapter Six: Hormone-Related Disorders
- Overview
- Contraception
- Overview
- Treatment
- Oral Contraceptives
- Depo-Provera
- Birth Control Patch
- Vaginal Ring
- Emergency Contraception and Early Option
- Implant
- Intrauterine Device (IUD)
- Endometriosis
- Overview
- Treatment
- Fibroids
- Overview
- Treatment
- Infertility
- Overview
- Treatment
- Menopause
- Overview
- Treatment
- Menstrual Disorders
- Amenorrhea
- Dysmenorrhea
- Sexual Dysfunction
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Alista
- Alprox-TD
- Asoprisnil
- Bijuva
- Bio-E-Gel
- BufferGel
- E2/DNG Pill
- Evamist
- FC Patch
- Femprox Cream
- Intrinsa
- LibiGel
- IoGen
- Lybrel
- Menopausal Levonorgestrel System
- NOMAC/E2
- Preven Emergency Contraceptive Kit
- Tanaproget
- Tostrelle
- Competitive Market
Chapter Seven: Osteoporosis
- Overview
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Aclasta
- AMG 162
- ALX 1-11
- Arzoxifene
- Banzedoxifene
- Denosumab
- Lasofoxifene (Oporia)
- Livial
- Oral Calcitonin
- Ostarine
- Preos
- S12911
- Competitive Market
Chapter Eight: Urinary Bladder Disorders
- Overview
- Cystitis
- Overview
- Treatment
- Incontinence
- Overview
- Treatment
- Overactive Bladder
- Treatment
- Alternative Treatments
- Interstitial Cystitis
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Competitive Market
Chapter Nine: Issues and Trends
- Women’s Health Initiative
- Perimenopausal Use of Contraceptives
- Fosamax Patents Void in European Market
- Insurance Coverage for Contraceptives
- Oral Contraceptives in Japan
- Ovarian Cancer Test
- New Pap Test Screening Guidelines
- Estrogen Labeling
- Osteoporosis Drug Opportunities in Asia
- OTC Plan B
- Cervical Cancer Vaccines
- Women’s Access to Health Care and Insurance
- Issues of Middle-Aged and Older Women
- Possible AIDS Vaccine
Chapter Ten: World Market Summary
- Overview
- Total Market Size and Forecast
- Market Analysis
Chapter Eleven: Competitor Profiles
- Industry Structure and Participants
- Akzo Nobel nv Organon International
- Amgen, Inc.
- AstraZeneca PLC
- Barr Laboratories, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis International AG
- Pfizer, Inc.
- Procter & Gamble Company
- Roche
- Sanofi -Aventis
- Schering AG
- Serono International S.A.
- Wyeth
Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Market Summary: The Worldwide Market for Prescription Drugs for Women’s Healthcare 2000-2010
- Figure 1-1: The Market for Women’s Healthcare Trending in Revenues bySegment 2000-2010
Chapter Two: Introduction and Overview
- Table 2-1: World Life Expectancy at Birth in Selected Countries by Sex, 2005
- Figure 2-1: Female Advantage in Life Expectancy at Birth in Selected Countries, 2005 (Difference, in Years, between Females and Males)
- Table 2-2: World Population Growth: Total World Population and SelectedCountry or Regions by Sex, 2000-2025
- Figure 2-2: World Population Growth by Sex 2000-2025
- Figure 2-3: United States Population Growth by Sex 2000-2025
- Figure 2-4: Five Major European Countries* Population Growth bySex 2000-2025
- Figure 2-5: Japan Population Growth by Sex 2000-2025
- Table 2-3: World Female Population Growth by Selected Country/Region andAge Group, 2000-2025
- Figure 2-6: World Female Population Growth by Selected Age Group 2000-2025
- Figure 2-7: United States Female Population Growth by Selected AgeGroup 2000-2025
- Figure 2-8: Five Major European Countries* Female Population Growth bySelected Age Group 2000-2025
- Figure 2-9: Japan Female Population Growth by Selected Age Group 2000-2025
- Table 2-4: Estimated Female Prevalence of Autoimmune Diseases by Type(Chronic Fatigue Syndrome, Fibromyalgia, Rheumatoid Arthritis, Scleroderma, Sjogren’s Disease, Systemic Lupus Erythematosus) and Geographical Distribution (World, U.S., Europe, Japan), Five-Year Average 2000-2005
- Table 2-5: Estimated Incidence and Mortality of Female Cancers by Type(Breast, Cervical, Endometrial, Ovarian) and GeographicalDistribution (World, U.S., Europe, Japan), Five-YearAverage 2000-2005
- Table 2-6: Estimated Female Incidence/Prevalence of Gynecological and Sexually Transmitted Diseases by Type ((AIDS/HIV, Bacterial Vaginosis,Cervical Dysplasia, Chlamydia, Genital Herpes, Gonorrhea,Human Papilloma Virus, Hepatitis [Sexually Transmitted], Pelvic Inflammatory Disease, Syphilis, Toxic Shock Syndrome, YeastInfection) and Geographical Distribution (World, U.S., Europe,Japan), Five-Year Average 2000-2005
- Table 2-7: Gynecological and Sexually Transmitted Diseases Diagnostic Testing Procedure Volume by Type (Pap, Pelvic Exams, HIV Tests, OtherSTD Tests, Mammograms), Five-Year Average 2000-2005
- Table 2-8: Estimated World and U.S. Female Incidence/Prevalence of Hormone-Related Indications by Type (Contraception, Endometriosis, Fibroids, Infertility, Menopause), Five-Year Average 2000-2005
- Table 2-9: Estimated World and U.S. Contraceptive Use by Method ((Female Sterilization, Oral Pill, Implant, Injectable, IUD, Diaphragm, Female Condom, Other Methods), Five-Year Average 2000-2005
- Table 2-10: Estimated Female Prevalence of Osteoporosis by Type (Diagnosed,Low-Bone Mass [At Risk], Osteoporosis-related Fractures) and Geographical Distribution (World, U.S., Europe, Japan), Five Year Average 2000-2005
- Table 2-11: Estimated Female Incidence/Prevalence of Urinary Bladder Disordersby Type (UTI, Incontinence, Overactive Bladder, InterstitialCystititis) and Geographical Distribution (World, U.S., Europe,Japan), Five Year Average 2000-2005
- Table 2-12: Estimated Female Statistics Concerning Lifestyle PatternsContributing to Disease by Type of Behavior and Geographical Distribution (World, U.S., Europe, Japan), Five YearAverage 2000-2005
Chapter Three: Autoimmune Diseases
- Table 3-1: The World Market for Autoimmune Disease Drugs for Women by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2000-2010
- Figure 3-1: The World Market for Autoimmune Disease Drugs for WomenRevenues by Type 2000-2010
- Figure 3-2: The World Market for Autoimmune Disease Drugs for WomenShare by Type (Antidepressants, Antianxiety/Sedatives, NSAIDs, Biologicals [RA] Immunosuppressants, Other) 2005 & 2010
- Table 3-2: The World Market for Autoimmune Disease Drugs for WomenRevenues by Geographical Region (U.S., Europe, Japan,ROW) 2000-2010
- Figure 3-3: The World Market for Autoimmune Disease Drugs for WomenShare by Geographic Region 2005 and 2010
- Table 3-4: The World Market for Autoimmune Disease Drugs for WomenRevenues and Market Share by Supplier 2005
- Figure 3-4: The World Market for Autoimmune Disease Drugs for WomenMarket Share by Leading Supplier 2005
Chapter Four: Cancer
- Table 4-1: The World Market for Cancer Drugs for Women by Type (Anti-metabolites, Alkylating Agents, Hormone Therapy, BiologicTherapies) 2000-2010
- Figure 4-1: The World Market for Cancer Drugs for Women Revenues byType 2000-2010
- Figure 4-2: The World Market for Cancer Drugs for Women Share by Type2005 and 2010
- Table 4-2: The World Market for Cancer Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
- Figure 4-3: The World Market for Cancer Drugs for Women SharePercentage 2005 and 2010
- Table 4-3: Products in Development for Women’s Cancers (Product,Indication, Developer, Phase) 2005
- Table 4-4: The World Market for Cancer Drugs for Women Revenues andMarket Share by Supplier 2005
- Figure 4-4: The World Market for Cancer Drugs for Women Market Share by Leading Supplier 2005
Chapter Five: Gynecological Infections and Sexually Transmitted Diseases
- Table 5-1: Currently Available HIV Pharmaceuticals
- Table 5-2: Currently Marketed Bacterial Vaginosis Pharmaceuticals
- Table 5-3: Currently Marketed Chlamydia Pharmaceuticals
- Table 5-4: Currently Marketed Condyloma Treatments
- Table 5-5: Currently Marketed Herpes Virus Treatments
- Table 5-6: Currently Marketed Hepatitis Treatments
- Table 5-7: Currently Marketed PID Treatments
- Table 5-8: Currently Marketed Prescription Yeast Infection Treatments
- Table 5-9: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women by Type (Antibacterials, Antifungals, Antivirals) 2000-2010
- Figure 5-1: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women Revenues byType 2000-2010
- Figure 5-2: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women Share by Type2005 and 2010
- Table 5-10: The World Market for Gynecological Infection and Sexually Transmitted Disease Drugs for Women Revenues by GeographicalRegion (U.S., Europe, Japan, ROW) 2000-2010
- Figure 5-3: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women Share by GeographicRegion 2005 and 2010
- Table 5-11: Products in Development for Women’s Gynecological Infectionsand Sexually Transmitted Diseases (Product, Indication, Developer, Phase)
- Table 5-12: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women Revenues and MarketShare by Supplier 2005
- Figure 5-4: The World Market for Gynecological Infection and SexuallyTransmitted Disease Drugs for Women Market Share by Leading Supplier 2005
Chapter Six: Hormone-Related Disorders
- Table 6-1: Selected Oral Contraceptives Available 2005
- Table 6-2: Selected Hormone Replacement Therapies
- Table 6-3: The World Market for Hormone-Related Disorder Drugs forWomen by Type (Contraceptives, Infertility Agents, HormoneReplacents, Other Hormone Therapies) 2000-2010
- Figure 6-1: The World Market for Hormone-Related Disorder Drugs forWomen by Type 2000-2010
- Figure 6-2: The World Market for Hormone-related Disorder Drugs forWomen Share by Type 2005 and 2010
- Table 6-4: The World Market for Hormone-Related Disorder Drugs forWomen Revenues by Geographical Region (U.S., Europe, Japan,ROW) 2000-2010
- Figure 6-3: The World Market for Hormone-Related Disorder Drugs forWomen Share by Geographic Region 2005 and 2010
- Table 6-5: Hormonal Preparations in Research and Development for Women (Product, Indication, Developer, Phase)
- Table 6-6: The World Market for Hormone-Related Disorder Drugs forWomen Revenues and Market Share by Supplier 2005
- Figure 6-4: The World Market for Hormone-Related Disorder Drugs forWomen Market Share by Leading Supplier 2005
Chapter Seven: Osteoporosis
- Table 7-1: The World Market for Osteoporosis Drugs for Women Revenuesby Type (Bone Metabolism Regulators, Hormones/SERMs)2000-2010
- Figure 7-1: The World Market for Osteoporosis Drugs for Women Revenuesby Type 2000-2010
- Figure 7-2: The World Market for Osteoporosis Drugs for Women Shareby Type 2005 and 2010
- Table 7-2: The World Market for Osteoporosis Drugs for Women Revenuesby Geographical Region (U.S., Europe, Japan, ROW) 2000-2010
- Figure 7-3: The World Market for Osteoporosis Drugs for Women Share by Geographic Region 2005 and 2010Table 7-3: Products in Development for Osteoporosis (Product, Developer,Phase)
- Table 7-4: The World Market for Osteoporosis Drugs for Women Revenuesand Market Share by Supplier 2005
- Figure 7-4: The World Market for Osteoporosis Drugs for Women MarketShare by Leading Supplier 2005
Chapter Eight: Urinary Bladder Disorders
- Table 8-1: Medications That Can Affect Urination
- Table 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type (Antibiotics, Anticholinergics/Antispasmodics, Cholinergics, Other) 2000-2010
- Figure 8-1: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Type 2000-2010
- Figure 8-2: The World Market for Urinary Bladder Disorder Drugs for Women Share by Type 2005 and 2010
- Table 8-3: The World Market for Urinary Bladder Disorder Drugs for Women Revenues by Geographical Region (U.S., Europe, Japan, ROW)2000-2010
- Figure 8-3: The World Market for Urinary Bladder Disorder Drugs forWomen Share by Geographic Region 2005 and 2010
- Table 8-4: Products in Development for Urinary Disorders (Product,Indication, Developer, Phase)
- Table 8-5: The World Market for Urinary Bladder Disorder Drugs forWomen Revenues and Market Share by Supplier 2005
- Figure 8-4: The World Market for Urinary Bladder Disorder Drugs forWomen Market Share by Leading Supplier 2005
Chapter Ten: World Market Summary
- Table 10-1: The Worldwide Market for Prescription Drugs in Women’sHealth, Revenues by Segment (Autoimmune, Cancer, Gynecologic Infections and STDs, Hormones, Osteoporosis, Urinary Bladder Disorders), 2000-2010
- Figure 10-1: The Market for Women’s Healthcare Revenues bySegment 2000-2010
- Figure 10-2: The Market for Women’s Healthcare Market Share byType 2005 and 2010
- Table 10-2: Women’s Health Revenues and Segments of Participation byLeading Market Participants 2005
Other users found this report page using the following search terms: women’s health Autoimmune diseases breast cancer cervical cancer ovarian cancer uterine cancer Gynecological disorders Sexually Transmitted Diseases Osteoporosis Urinary Disorders market prescription fibromyalgia entriva product womens online share order growth
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.